Watch EVMN. Know when insiders buy.
One email the day a filing lands. Free.
EVMN
Evommune, Inc.
10.54
−0.02 −0.19%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
38
FLAG · shorts 38
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $382.5MP/E 1.9DIV YIELD —FCF YIELD -19.52%REV TTM $10MNET INCOME −$94.7MNET CASH —52W 10.54 – 31.57SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$34.9M | −$32.2M | — | -0.89 | −$20.3M | $183K | −$20.5M | Aug 6 |
| Q1 2026 · Mar 31 | $0 | −100.0% | — | −$24M | −$21.7M | — | -0.64 | −$27.5M | $83K | −$27.6M | May 7 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$29.7M | −$28.3M | — | 15.14 | −$16.7M | $104K | −$16.8M | Mar 5 |
| Q3 2025 · Sep 30 | $10M | — | — | −$13.3M | −$12.5M | — | -8.07 | −$9.6M | $131K | −$9.8M | Dec 11 |
| Q2 2025 · Jun 30 | $0 | — | — | −$23M | −$13.6M | — | -8.80 | −$26.2M | $0 | −$26.2M | Aug 6 |
| Q1 2025 · Mar 31 | $3M | — | — | −$15M | −$14.6M | — | -9.48 | −$23.9M | $0 | −$23.9M | May 7 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$21.5M | −$20.7M | — | -14.60 | −$18.5M | $0 | −$18.5M | Mar 5 |
| Q3 2024 · Sep 30 | — | — | — | −$16.5M | −$15.9M | — | -10.47 | — | — | — | Dec 11 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $13M | — | −$81.1M | −$68.9M | -529.8% | -11.22 | −$76.4M | $235K | −$76.7M | — | — |
| FY2024 · to Dec 31 | $7M | — | −$70M | −$66.8M | -954.4% | -45.29 | −$58.2M | $88K | −$58.3M | — | — |
Every number comes from Evommune, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.